开发和验证PARCOMS复合尺度,用于评估帕金森病的疾病进展和治疗效果
Gil L'Italien1, Basia Rogula2, Lauren Powell2
1Biohaven Pharmaceuticals, Inc, 215 Church St, New Haven, CT, USA.
Neurology and therapy
|June 15, 2025
概括
新的帕金森复合量表 (PARCOMS) 显示对帕金森病进展的反应比MDS-UPDRS更强. 这些特定阶段的尺度为帕金森病患者提供了改善的临床衰退评估.
科学领域:
- 神经学 神经学
- 临床评估 临床评估
- 帕金森病研究 帕金森病研究
背景情况:
- 标准的帕金森病 (PD) 评估可能会错过早期进展的细微差别.
- 需要敏感的措施来跟踪PD在疾病阶段和治疗状态的演变.
研究的目的:
- 开发帕金森复合量表 (PARCOMS) 以提高对PD临床衰退的反应能力.
- 使用运动障碍学会统一帕金森病评分表 (MDS-UPDRS) 项目来构建尺度.
主要方法:
- 来自帕金森病进展标记计划 (PPMI) 的患者根据治疗和运动并发症分为三个队列.
- 部分最小平方 (PLS) 回归选择了基于响应性的PARCOMS-Motor和PARCOMS-Non-Motor的MDS-UPDRS项目.
- 使用变化值的平均标准偏差比率 (MSDR) 估计的响应性.
主要成果:
- PARCOMS-Motor显示显著增加了MSDR:13.1% (未经治疗),78.2% (经过治疗,没有并发症),100.6% (经过治疗,并发症).
- 帕科姆斯非运动性MSDR增加:13.9% (未经治疗),6.8% (经过治疗,没有并发症),20.7% (经过治疗,并发症).
- 关键的贡献者包括床上转身/言语 (运动) 和认知/尿道问题 (非运动),反映了异质的进展.
结论:
- 与MDS-UPDRS相比,开发的PD阶段特定复合测量 (PARCOMS) 显示出更高的变化灵敏度.
- 根据疾病阶段量身定制的加权复合材料提高了对帕金森病进展的评估.
- PARCOMS提供了一个更具响应性的工具,用于跟踪帕金森病的临床衰退.
相关概念视频
01:15Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
01:24Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
40
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
40